Linezolid

Description

1. Product Overview
Linezolid is a high-purity synthetic oxazolidinone antibiotic active pharmaceutical ingredient (API) designed for the manufacture of sterile and oral dosage forms targeting Gram-positive bacterial infections, including MRSA and VRE. Its primary industrial use lies in large-scale formulation of hospital-critical therapeutics where resistance management is paramount. The key value proposition is exceptional batch-to-batch consistency yielding superior dissolution profiles and terminal sterilization compatibility. Strategically, it is indispensable for pharmaceutical manufacturers seeking to secure supply chains against generic erosion and antibiotic resistance trends.

2. Key Specifications & Technical Characteristics

• Chemical composition: (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, synthetic, non-beta-lactam

• Purity grade: ≥99.5% (by HPLC), EP/USP/BP compliant, residual solvents within ICH Q3C limits

• Physical form: White to off-white crystalline powder, particle size D90 <50 µm (micronized grade available), bulk density 0.4–0.6 g/mL

• Packaging options: Multilayer laminated aluminum foil bags (1–5 kg), fiber drums with LDPE liners (10–25 kg), export-worthy palletized units

• Shelf life: 36 months from manufacture when stored at 15–25°C, protected from light and moisture

3. Core Industrial Applications

• Primary industry: Large-scale pharmaceutical manufacturing (branded generics, biosimilar-adjacent antibiotics, hospital injectables)

• Case use 1: IV bag and pre-filled syringe production – linezolid’s aqueous stability outpercomes vancomycin in room-temperature storage

• Case use 2: Oral tablet/suspension manufacturing – higher bioavailability (100%) vs. comparators, enabling lower dose and reduced side-effect profile

• Cost advantage: Single-step synthesis route reduces purification overhead by 22% vs. conventional oxazolidinone production

4. Competitive Advantages

• Quality consistency: Zero batch rejection in three consecutive third-party audits (SGS, Eurofins, USP); polymorph Form II guaranteed every shipment

• Supply reliability: Dedicated 6,000 L reactor train with 99.7% on-time delivery rate over 18 months across four continents

• Logistics capability: Temperature-controlled dispatch from regional hubs (NJ, Rotterdam, Shanghai) with 5-day door-to-door ocean-to-warehouse

• Price competitiveness: Tiered pricing achieving 8–12% under European incumbents at annual contract volumes >500 kg

• Sustainability: Solvent recovery rate >85% (ethyl acetate, THF); EHSG-certified manufacturing with reduced heavy-metal catalyst use

5. Commercial & Supply Information

• Minimum order quantity (MOQ): 25 kg (standard pharmaceutical grade) | 10 kg for micronized/sterile-grade

• Bulk 20MT loading capacity: Equivalent to 2,000 kg net (100 fiber drums of 20 kg each per 20FT container, palletized)